36855-69-3

Basic information

• Product Name: 4-amino-N-(1H-benzimidazol-2-yl)benzamide
• Synonyms: 4-amino-N-(1H-benzimidazol-2-yl)benzamide
• CAS NO: 36855-69-3
• Molecular Weight: 252.275
• Mol File: 36855-69-3.mol
• Article Data: 4

Chemical Properties

• CAS DataBase Reference: 4-amino-N-(1H-benzimidazol-2-yl)benzamide(CAS DataBase Reference)
• NIST Chemistry Reference: 4-amino-N-(1H-benzimidazol-2-yl)benzamide(36855-69-3)
• EPA Substance Registry System: 4-amino-N-(1H-benzimidazol-2-yl)benzamide(36855-69-3)

Safety Data

• Hazardous Substances Data: 36855-69-3(Hazardous Substances Data)

Upstream product

• 36855-68-2 4-nitro-N-(1H-benzimidazol-2-yl)benzamide 
• 934-32-7 1H-benzimidazol-2-amine 
• 66493-39-8 4-(N-tert-butoxycarbonyl)aminobenzoic acid 
• 122-04-3 4-nitro-benzoyl chloride 
• 16106-38-0 4-aminobenzoyl chloride 

Relevant articles and documents

Amido pyrimidine compound

The invention provides an amido pyrimidine compound with a novel structure as shown in a formula (I) and a preparation method and application of the amido pyrimidine compound. The amido pyrimidine compound is a compound shown as the formula (I), or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer or tautomer thereof and the like. The amido pyrimidine compound provided bythe invention has a relatively good proliferation inhibition effect on various cancer cells; according to the present invention, the compound has characteristics of low tumor cell inhibition concentration, significantly-improved compound activity, good tumor cell selectivity and good solubility, and is expected to be a specific drug for treatment of malignant tumor cell abnormal proliferation diseases caused by EGFR mutation.

Synthesis, crystal structure determination and antiproliferative evaluation of novel benzazoyl benzamides

A series of benzazoyl-benzamides containing different substituents (7-17) were synthesized by condensation of 2-aminobenzazole derivatives (3a-6) with p-substituted benzoyl chlorides. All compounds were characterized by IR, 1H and 13C NMR, MS and elemental analysis. Crystal structure was determined for the compound (9). Some of the new synthesized compounds (7-17) were screened for antitumor activities. Based on presented in vitro screening results we may conclude that compounds (10, 15a, 15b and 16) showed accentuated cell growth inhibitory activity.